Vitamin K epoxide reductase complex subunit 1 gene polymorphism is associated with atherothrombotic complication after drug-eluting stent implantation: 2-Center prospective cohort study - 07/08/11
Résumé |
Background |
Single nucleotide polymorphisms of vitamin K epoxide reductase complex subunit 1 (VKORC1) was reported to have association with arterial vascular disease. We investigated whether single nucleotide polymorphism of VKORC1 +2255 is associated with clinical outcomes among patients who underwent drug-eluting stent (DES) implantation.
Methods |
We prospectively collected genomic DNA in patients who underwent DES deployment from September 2003 to December 2006 and compared clinical outcomes according to their VKORC1 genotype at the locus + 2255 (rs 2359612). The primary end point was composite of atherothrombotic events (cardiac death, myocardial infarction, and nonhemorrhagic stroke).
Results |
Mean follow-up duration was 631 ± 251 days. Genotyping was completed in 764 cases (TT genotype [n = 640, 83.8%] vs non-TT [CC or CT] genotype [n = 124, 16.2%]). Non-TT group showed more composite events than TT group (7.3% vs 3.0%, P = .032). In the Cox regression analysis, non–TT genotype of VKORC gene was a significant predictor of atherothrombotic events (hazard ratio 2.56, 95% confidence interval 1.14-5.78). In the event-free survival analysis, non–TT group also showed significantly poorer cardiovascular events-free survival rate than TT group (P = .02).
Conclusions |
VKORC1 genotype is associated with cardiovascular events in patients with DES implantation, suggesting the role of coagulation system.
Le texte complet de cet article est disponible en PDF.Plan
| This study was supported by the grants from the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (0412-CR02-0704-0001), and the Innovative Research Institute for Cell Therapy (A062260). |
Vol 157 - N° 5
P. 908-912 - mai 2009 Retour au numéro
Article précédent
- The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents
- Michelle J. Butler, David Eccleston, David J. Clark, Andrew E. Ajani, Nick Andrianopoulos, Angela Brennan, Gishel New, Alexander Black, Gregory Szto, Chris M. Reid, Bryan P. Yan, James A. Shaw, Anthony M. Dart, Stephen J. Duffy, on behalf of the Melbourne Interventional Group (MIG)
- Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial
- A. Selcuk Adabag, Salima Mithani, Basel Al Aloul, Dorothea Collins, Stefan Bertog, Hanna E. Bloomfield, for The Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?